Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma.


Autoria(s): Bihl F.; Berger C.; Chisholm J.V.; Henry L.M.; Bertisch B.; Trojan A.; Nadal D.; Speck R.F.; Flepp M.; Brander C.; Mueller N.J.; Swiss HIV Cohort Study
Data(s)

2009

Resumo

Kaposi's sarcoma-associated herpesvirus (KSHV) specific T cell responses and KSHV viremia were analyzed in seven HIV-infected patients with active Kaposi's sarcoma lesions who initiated highly active antiretroviral therapy, and were compared between patients with improved Kaposi's sarcoma and those with progressive Kaposi's sarcoma requiring further systemic chemotherapy. Patients with controlled Kaposi's sarcoma disease demonstrated undetectable Kaposi's sarcoma viremia together with KSHV-specific CD8 T cells secreting interferon-gamma and tumor necrosis factor-alpha, whereas progressors showed increasing viremia with weak or no T-cell responses. These data point toward a potential role of KSHV-specific immunity in the control of AIDS-associated Kaposi's sarcoma.

Identificador

https://serval.unil.ch/?id=serval:BIB_2CFA1626D202

isbn:1473-5571 (Electronic)

pmid:19609199

doi:10.1097/QAD.0b013e3283300a91

isiid:000269908800019

Idioma(s)

en

Fonte

Aids, vol. 23, no. 14, pp. 1918-1922

Palavras-Chave #Acquired Immunodeficiency Syndrome/complications; Acquired Immunodeficiency Syndrome/drug therapy; Acute Disease; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes/immunology; Disease Progression; Humans; Immunity, Cellular; Sarcoma, Kaposi/immunology; Sarcoma, Kaposi/virology; Treatment Outcome; Viral Load
Tipo

info:eu-repo/semantics/article

article